Article
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Gut and liver - 15 May 2018
Lee Hye Won, Oh Se Rim, Kim Dong Yun, Jeong Yechan, Kim Seungtaek, Kim Beom Kyung, Kim Seung Up, Kim Do Young, Ahn Sang Hoon, Han Kwang-Hyub, Park Jun Yong
Abstract excerpt
BACKGROUND/AIMS: The treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection. We investigated the real-world efficacy, changes in liver stiffness and noninvasive fibrosis markers, and the safety of DCV+ASV treatment in Korean patients. METHODS: In total, 363 patients with chronic hepatitis C were treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.